Alternative Splicing Yields Insights Into Cancer Metabolism And Potential New Drug Targets
This article was originally published in Start Up
For the first time, cancer researchers have shown that a variant of the EGF receptor often amplified in glioblastoma upregulates a specific splicing protein that in turn alters cancer metabolism. This increased understanding of the factors controlling so-called “alternative splicing” could offer up a range of new therapeutic approaches in GBM, other cancers, and potentially other diseases.
You may also be interested in...
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.
Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.